Streptomycin has been found to be active principally against certain gram-negative organisms and acid-fast bacilli. Its trial in the management of granuloma inguinale, while not entirely justified in view of the controversial concept of the nature of the pathogenic agent, was warranted on the basis that the need for a more effective and specific form of therapy of granuloma inguinale was greatly desired. Before the advent of the antibiotics the modem therapy of granuloma inguinale generally involved the use of one of a number of antimony compounds. These have varied from the intravenous injection of such antimonials as antimony potassium tartrate and "diramin" (an aqueous solution of the products resulting from the reaction between antimony catechol and triisopropanolamine in the presence of propylene glycol) to the intramuscular administration of the less toxic and more stable derivatives, such as lithium antimony thiomalate ("anthiomaline") and stibophen.1
In addition, adjuncts to antimony
KUPPERMAN HS, GREENBLATT RB, DIENST RB. STREPTOMYCIN IN THE THERAPY OF GRANULOMA INGUINALE. JAMA. 1948;136(2):84–89. doi:10.1001/jama.1948.02890190012004
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: